已收盤 08-08 16:00:00 美东时间
-0.240
-2.64%
Cogent Biosciences reported positive results from the SUMMIT trial for bezuclastinib in NonAdvanced Systemic Mastocytosis patients, achieving statistical significance across primary and key secondary endpoints. The company also announced financial results, securing $800 million in capital through debt financing and a public offering, positioning it to fund operations through 2027. Upcoming milestones include top-line results from PEAK and APEX tr...
08-05 12:00
Needham analyst Mike Cikos reiterates Cognyte Software (NASDAQ:CGNT) from Hold to Hold.
07-28 17:51
New customer selects Cognyte over incumbent, citing superior technology, regional references and proven operational valueCognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global leader in software-driven technology for
07-23 21:49
Cognyte Software (NASDAQ:CGNT) said on Monday that its board of directors has approved a new share repurchase program. The company completed the repurchase program previously authorized by the board ...
07-15 04:09
Company completes previously announced programNew program reaffirms board's commitment to delivering shareholder valueCognyte Software Ltd. (NASDAQ:CGNT), a global leader in software-driven technology for investigative
07-15 04:00
Cognyte Software shares are trading lower. The company reported Q1 financial re...
06-12 02:31
Additional Financial and Operational Data for the First Quarter Ended April 30, 2025Q1 FYE26 Total Software revenue increased by $6.2 million, compared to last fiscal year, aligned with our growth strategy.Q1 FYE26
06-11 19:19
Companies Reporting Before The Bell • Victoria's Secret (NYSE:VSCO) is projecte...
06-11 16:32
Cognyte Software and GitLab Inc are the last two companies to report in Needham analyst Mike Cikos' coverage of first-quarter earnings season.
06-10 01:54
Needham analyst Mike Cikos reiterates Cognyte Software (NASDAQ:CGNT) from Hold to Hold.
05-22 19:12